Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 7/20 | 0.35 |
| ▸ | HTR2A | P28223 | 5/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128011 | 0.97 | KCNH2 (0.47) | KCNH2HRH3SMYD2CCR5FFAR4 | |
| SCHEMBL4125759 | 0.96 | KCNH2 (0.51) | KCNH2HRH3SMYD2CCR5FFAR4 | |
| SCHEMBL4128894 | 0.91 | KCNH2 (0.46) | KCNH2HRH3FFAR4KDM4EHTT | |
| SCHEMBL4130153 | 0.87 | KCNH2 (0.51) | KCNH2HRH3SMYD2CCR5KDM4E | |
| SCHEMBL4134395 | 0.85 | KCNH2 (0.49) | KCNH2HRH3SMYD2CCR5KDM4E | |
| SCHEMBL4133463 | 0.83 | KCNH2 (0.54) | KCNH2HRH3CCR5KDM4EHTT | |
| SCHEMBL3598224 | 0.83 | KCNH2 (0.57) | KCNH2HRH3HRH2HRH1 | |
| SCHEMBL4667626 | 0.83 | KCNH2 (0.42) | KCNH2HRH3FFAR4KDM4EHTT | |
| SCHEMBL4134243 | 0.82 | KCNH2 (0.54) | KCNH2KDM4EHTTALDH1A1 | |
| SCHEMBL4127866 | 0.81 | KCNH2 (0.47) | KCNH2HRH3SMYD2KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | claimed |
| WO-2006135316-A1 | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | claimed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135316-A1 | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 6/4885HRH3 448/4885SMYD2 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.